A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD)

Investigator: R. Keith McBurnett, PhD
Sponsor: Sunovion Pharmaceuticals Inc

Location(s): United States


This is a randomized, double blind, multicenter, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in adults with ADHD. An 8-week study evaluating an investigational medication.

Study design

Eligible participants may receive psychiatric evaluation, medical exam, blood draws, and electrocardiogram (ECG) to determine eligibility.

Eligible participants will return to the clinic for 10 weeks for evaluations and will receive study drug or placebo. A placebo resembles the study drug, but has no active ingredients.

All participation is voluntary; you can stop anytime.

Participant requirements

Adults between 18 and 55 years old